ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. McKay on Statin Use in Patients With mRCC

Rana R. McKay, MD
Published: Thursday, Feb 26, 2015

Rana R. McKay, MD, Instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.

In this analysis, statin users demonstrated an overall survival of 25.6 months compared with 18.9 months for non-users. This improvement was seen among patients receiving VEGF targeted therapy or mTOR targeted therapy. However, McKay says, no benefit was seen among patients receiving interferon or cytokine-based therapies.

Because of this, McKay says, statin use may be synergistic with VEGF or mTOR targeted therapies.

<<< View more from the 2015 GU Cancer Symposium

Rana R. McKay, MD, Instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.

In this analysis, statin users demonstrated an overall survival of 25.6 months compared with 18.9 months for non-users. This improvement was seen among patients receiving VEGF targeted therapy or mTOR targeted therapy. However, McKay says, no benefit was seen among patients receiving interferon or cytokine-based therapies.

Because of this, McKay says, statin use may be synergistic with VEGF or mTOR targeted therapies.

<<< View more from the 2015 GU Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x